Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RELEASE MSS5: Nabiximols for Spasticity in Multiple Sclerosis
NCT04984278Phase 3Terminated
- Sponsor
- Jazz Pharmaceuticals plc
- Start
- Aug 2021
- Primary completion
- Nov 2022
- Modality
- Small Molecules
- Countries
- 5
01
Overview
Phase 3, randomised, double-blind trial of cannabis extract in multiple sclerosis (MS) (2 arms), sponsored by Jazz Pharmaceuticals plc. Primary endpoint: Change From Baseline in Lower Limb Muscle Tone-6 at Day 51. Started Aug 2021; status: terminated.
02
Drugs
cannabis extract
03
Conditions
multiple sclerosis (MS)
Beyond the preview
Go deeper on NCT04984278.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04984278.